Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491279 | 0.86 | NPSR1 (0.47) | ALDH1A1TDP1TSHRPOLBLMNA | |
| SCHEMBL2492917 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHR | |
| SCHEMBL2494124 | 0.81 | CYP4F2 (0.48) | ALDH1A1TDP1HPGDPOLBCYP3A4 | |
| SCHEMBL2491276 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL25234798 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRHPGDPOLB | |
| SCHEMBL5205707 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRHPGDPOLB | |
| SCHEMBL4657108 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TDP1TSHRHPGDPOLB | |
| SCHEMBL671038 | 0.74 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRHPGDPOLB | |
| SCHEMBL27784256 | 0.74 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRHPGDPOLB | |
| SCHEMBL11695700 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TDP1TSHRHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| CN-101578259-A | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators | VALEANT PHARMACEUTICALS INT (US) | 2009-11-11 | — | — | CN | disclosed |
| EP-2086925-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | ALDH1A1 1031/4885TDP1 1051/4885TSHR 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.